Literature DB >> 28943144

The epidemiology, antibiograms and predictors of mortality among critically-ill patients with central line-associated bloodstream infections.

Shin-Huei Kuo1, Wei-Ru Lin2, Jun-You Lin3, Chung-Hao Huang1, Ya-Ting Jao4, Pei-Wen Yang4, Jong-Rung Tsai5, Wen-Hung Wang1, Yen-Hsu Chen3, Ching-Tzu Hung6, Po-Liang Lu3.   

Abstract

BACKGROUND/
PURPOSE: For high risk of central line-associated bloodstream infections (CLABSIs) in patients of intensive care units (ICUs) and scarcely epidemiology and therapeutic recommendations in Asia, we aimed to evaluate the annual change in epidemiology, antibiogram, and risk factors for 14-day mortality.
METHODS: A retrospective study of ICUs patients with CLABSIs at a medical center in Taiwan (2010-2016), where central line care bundle implemented since 2014, by reviewing clinical data, pathogens, and the antibiogram.
RESULTS: Gram-negative bacteria (59.3%) were main microorganisms of CLABSIs, and 9.0% of all GNB were MDROs. Acinetobacter spp., Enterobacter spp., and Stenotrophomonas maltophilia were the most frequently isolated. In multivariate analysis, malignancy, inadequate empirical antimicrobial therapy, inadequate definite antimicrobial therapy, and infection by fungi or multidrug-resistant organisms (MDROs) were associated with 14-day mortality (all p < 0.05). The CLABSI incidence rate decreased from 5.54 to 2.18 per 1000 catheter-day (from 2014 to 2015) with improved compliance to care bundle. Carbapenem and aminoglycoside were suitable empirical drugs in the hospital setting when GNB is predominant for CLABSI. Significant decreasing susceptibility of ampicillin/sulbactam in Enterobacter spp. (36.7%-0.0%), and ampicillin/sulbactam (12.5%-0.0%), ceftazidime (100.0%-52.9%), and tigecycline (87.5%-35.3%) in Serratia marcescens.
CONCLUSION: We identified Gram-negative bacteria as leading pathogens of CLABSIs in a Taiwan medical center, and good compliance to care bundle is associated with reduced CLABSI incidence rate. Malignancy, infection by MDROs or fungi, inadequate empirical or definite antimicrobial therapy are significant factors for 14-day mortality.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Antimicrobial susceptibility; Bloodstream infection; Central line; Epidemiology; Intensive care unit; Mortality

Mesh:

Substances:

Year:  2017        PMID: 28943144     DOI: 10.1016/j.jmii.2017.08.016

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  6 in total

1.  Effects of Inappropriate Administration of Empirical Antibiotics on Mortality in Adults With Bacteraemia: Systematic Review and Meta-Analysis.

Authors:  Yuan-Pin Hung; Ching-Chi Lee; Wen-Chien Ko
Journal:  Front Med (Lausanne)       Date:  2022-05-30

2.  Hypochlorous Acid-Generating Electrochemical Catheter Prototype for Prevention of Intraluminal Infection.

Authors:  Edison J Cano; Laure Flurin; Abdelrhman Mohamed; Kerryl E Greenwood-Quaintance; Yash S Raval; Haluk Beyenal; Robin Patel
Journal:  Microbiol Spectr       Date:  2021-10-27

3.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

4.  Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection.

Authors:  Jason P Burnham; Rebecca P Rojek; Marin H Kollef
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

5.  Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia.

Authors:  Johny Fares; Melissa Khalil; Anne-Marie Chaftari; Ray Hachem; Ying Jiang; Hagop M Kantarjian; Issam I Raad
Journal:  Open Forum Infect Dis       Date:  2019-09-28       Impact factor: 3.835

6.  Twitching motility of Stenotrophomonas maltophilia under iron limitation: In-silico, phenotypic and proteomic approaches.

Authors:  Kalidasan V; Vasantha Kumari Neela
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.